Sanofi Pasteur uses novel technology for development of a 2nd-gen influenza vaccine
Researchers at Sanofi Pasteur have published pre-clinical data on a novel, computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. The vaccine strategy elicited a broad antibody response against seasonal and pandemic isolates in mice, demonstrating its potential as a 'subtype universal' vaccine.